ABL Diagnostics, a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories, has announced the expansion of its HIV genotyping menu of applications with the release of a new revolutionary assay, DeepChek® Assay HIV-1 Full PR/RT/INT Drug Resistance. The new assay targets the protease, the reverse transcriptase and the integrase genes which are the key targets for assessing the level of resistance of the drugs currently prescribed for treating patients infected by the HIV-1 virus.
Analytical outcomes performed using both RNA and proviral DNA samples achieve excellent outcomes in terms of specificity and sensitivity (with a Limit of Detection (LOD) below 1000 copies/mL). This assay, currently available for Research Use Only (RUO), is a good candidate to go for IVDR marking. It would confer to virologists an efficient way to perform genotyping tests for naïve and treatment-experienced patients.
The design of the assay, with one single PCR for covering the entire length of all genes, provides to laboratory great efficiency in terms of turnaround time and hands-on time. Tested with different combinations of next generation sequencing (NGS) systems and the DeepChek®-HIV Software, ABL Diagnostics can provide an end-to-end solution for microbiology labs.
Dr. Sofiane Mohamed, Head of Research and Development at ABL Diagnostics, said: “With the development of this new assay in our laboratory in Woippy, we had to face substantial technical challenges that we were able to overcome with the entire team’s focus and dedication. We keep innovating by constantly adapting our strategy to fulfil the natural evolutions of the virus, to overcome the related scientific challenges, and to meet regulatory requirements.”
Dimitri Gonzalez, Head of Diagnostics, expressed his satisfaction, saying, “The release of this disruptive assay strengthens the leading position of the company in the field of Microbiology genotyping through sequencing. Our DeepChek® technology is an open system allowing to pool different microbiology applications in the same sequencing run.”
ABL Diagnostics has released a revolutionary new kit, DeepChek® Assay HIV-1 Full PR/RT/INT Drug Resistance, to strengthen their expertise and leadership in HIV drug resistance testing by genotyping through sequencing. The new assay targets the protease, the reverse transcriptase and the integrase genes which are key targets for assessing the level of resistance of the drugs currently prescribed for treating HIV-1. Analytical outcomes performed using both RNA and proviral DNA samples achieve excellent outcomes in terms of specificity and sensitivity, with a Limit of Detection (LOD) below 1000 copies/mL. This assay is a good candidate to go for IVDR marking and would confer to virologists an efficient way to perform genotyping tests for naïve and treatment-experienced patients.
Dr. Sofiane Mohamed, Head of Research and Development at ABL Diagnostics, commented: “We had to face substantial technical challenges that we were able to overcome with the entire team’s focus and dedication. We keep innovating by constantly adapting our strategy to fulfil the natural evolutions of the virus, to overcome the related scientific challenges, and to meet regulatory requirements.”
Dimitri Gonzalez, Head of Diagnostics, added: “The release of this disruptive assay strengthens the leading position of the company in the field of Microbiology genotyping through sequencing. Our DeepChek® technology is an open system allowing to pool different microbiology applications in the same sequencing run.”
ABL Diagnostics, a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories, has announced the release of a revolutionary new kit, DeepChek® Assay HIV-1 Full PR/RT/INT Drug Resistance. The assay is designed to target the protease, the reverse transcriptase and the integrase genes which are key targets for assessing the level of resistance of the drugs currently prescribed for treating HIV-1.
Analytical outcomes performed using both RNA and proviral DNA samples have achieved excellent outcomes in terms of specificity and sensitivity, with a Limit of Detection (LOD) below 1000 copies/mL. This assay is a good candidate to go for IVDR marking and would confer to virologists an efficient way to perform genotyping tests for naïve and treatment-experienced patients.
Dr. Sofiane Mohamed, Head of Research and Development at ABL Diagnostics, commented: “We had to face substantial technical challenges that we were able to overcome with the entire team’s focus and dedication. We keep innovating by constantly adapting our strategy to fulfil the natural evolutions of the virus, to overcome the related scientific challenges, and to meet regulatory requirements.”
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.